Evaluation of the Prospective Observation of erythropoietin-administration for the treatment of Acute Myocardial Infarction-II
- Conditions
- Acute Myocardial Infarction
- Registration Number
- JPRN-UMIN000005721
- Lead Sponsor
- Cardioprotection Workshop
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 600
1) Patients with first-time myocardial infarction
2) Patients with ST-elevation acute myocardial infarction (AMI) who have successful reperfusion by PCI within 12 hours after the symptom onset.
3) Patients whose ejection fraction at enrollment is <50% on UCG or LVG.
4) Age: over 20 years old, under 80 years old
5) Patients who agreed with participation to the trial in writing.
1) Patients with significant stenotic lesions which require revascularization.
2) Patients who resulted in obviously impaired reperfusion.
3) Patients with Killip class III or IV, or cardiogenic shock at admission.
4) Patients with advanced renal or hepatic dysfunction (Cre more than 2mg/dl, or T-Bil more than 3mg/dl)
5) Patients with blood pressure more than 140/90mmHg after PCI.
6) Hematocrit more than 54% after PCI.
7) Patients who exhibit atrial fibrillation after PCI.
8) Patients who has been diagnosed with malignant hypertension.
9) Patients who has previously received treatment with rhEPO.
10) Patients who received a blood transfusion in the last three months.
11) Patients who is or has been diagnosed with cancer in the past 5 years.
12) Patients who are complicated with severe infection such as pneumonia or sepsis.
13) Patients who are contraindicated to aspirin or thienopyridine derivatives.
14)Women who is pregnant, breastfeeding, or has a possibility for pregnancy.
15) Patients whom researchers judged that they are not appropriate to participate this trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method